Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDGN201 TARGTEPO · 1 trial · 2 indications
Due to the small sample size and the dispersion of total EPO secretion, the efficacy analyses were performed on all of the patients as a single cohort of intended dose between 25 and 45 U/Kg/d.
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day) |
| Group B | EXPERIMENTAL | MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day) |
| Group C | EXPERIMENTAL | MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day) |
| Name | Type | Description |
|---|---|---|
| MDGN201 TARGTEPO | BIOLOGICAL | Erythropoietin secreted by TARGTEPO transduced with MDGN201 |
Inclusion Criteria: 1. For ESRD patients: Subject diagnosed with Anemia due to Chronic Renal Failure CKD stage 5 on hemodialysis treatment for at least 6 months. Average Hb during last month between 9 to 12g/dL. 2. Kt/V \>1 3. INR not higher than 1.2 4. Serum albumin \>3.5 5. Subjects with adequate...
Top 20 of 25 competitors
MDGN201 TARGTEPO is an investigational monoclonal antibody being developed for chronic kidney disease (CKD). It was studied in a Phase 1 clinical trial for the treatment of anemia in patients with CKD and end-stage renal disease (ESRD). The drug is still in clinical development and is not approved by the FDA.
MDGN201 TARGTEPO is being developed by Avalo Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AVTX. The company is conducting clinical research on this investigational drug for chronic kidney disease.
MDGN201 TARGTEPO is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by the FDA or any other regulatory authority for commercial use.
MDGN201 TARGTEPO has one completed clinical trial registered under NCT02117427, titled "TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)." This Phase 1 study enrolled 11 participants in Israel and was a controlled, non-randomized, open-label trial.
Yes, MDGN201 TARGTEPO is also known as TARGTEPO. The drug is referred to by both names in clinical research. It is an investigational monoclonal antibody being studied for anemia associated with chronic kidney disease and end-stage renal disease.